PIP4K2B Protein, Human (His)

PIP4K2B Protein actively synthesizes phosphatidylinositol 4,5-bisphosphate, preferring GTP over ATP in PI(5)P phosphorylation, with enzymatic activity linked to physiological GTP levels. Its unique GTP-sensing ability critically aids metabolic adaptation. PIP4K2B, part of PIP4Ks, negatively influences insulin signaling via a catalytic-independent mechanism, interacting with PIP5Ks to suppress PIP5K-mediated PtdIns(4,5)P2 synthesis, hindering insulin-dependent conversion to PtdIns(3,4,5)P3. This multifaceted role emphasizes PIP4K2B's significance in modulating key signaling pathways for cellular homeostasis and metabolic responsiveness. PIP4K2B Protein, Human (His) is the recombinant human-derived PIP4K2B protein, expressed by E. coli, with N-10*His labeled tag. The total length of PIP4K2B Protein, Human (His) is 415 a.a., with molecular weight of 53.3 kDa.

PIP4K2B Protein actively participates in the biosynthesis of phosphatidylinositol 4,5-bisphosphate, demonstrating a preference for GTP over ATP in the phosphorylation of PI(5)P, and its enzymatic activity is intricately linked to physiological GTP concentrations. The protein's unique GTP-sensing ability plays a critical role in metabolic adaptation. Notably, PIP4Ks, including PIP4K2B, exert a negative regulatory influence on insulin signaling through a catalytic-independent mechanism. They form interactions with PIP5Ks, effectively suppressing PIP5K-mediated synthesis of PtdIns(4,5)P2 and impeding insulin-dependent conversion to PtdIns(3,4,5)P3. This multifaceted role underscores the importance of PIP4K2B in modulating key signaling pathways that contribute to cellular homeostasis and metabolic responsiveness.

Human

E. coli

N-10*His

P78356 (S2-T416)

8396  [NCBI]

SSNCTSTTAVAVAPLSASKTKTKKKHFVCQKVKLFRASEPILSVLMWGVNHTINELSNVPVPVMLMPDDFKAYSKIKVDNHLFNKENLPSRFKFKEYCPMVFRNLRERFGIDDQDYQNSVTRSAPINSDSQGRCGTRFLTTYDRRFVIKTVSSEDVAEMHNILKKYHQFIVECHGNTLLPQFLGMYRLTVDGVETYMVVTRNVFSHRLTVHRKYDLKGSTVAREASDKEKAKDLPTFKDNDFLNEGQKLHVGEESKKNFLEKLKRDVEFLAQLKIMDYSLLVGIHDVDRAEQEEMEVEERAEDEECENDGVGGNLLCSYGTPPDSPGNLLSFPRFFGPGEFDPSVDVYAMKSHESSPKKEVYFMAIIDILTPYDTKKKAAHAAKTVKHGAGAEISTVNPEQYSKRFNEFMSNILT

53.3 kDa

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.